Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity
Zydus Cadila gets USFDA nod for arthritis drug with 180-days exclusivity Zydus was the first abbreviated new drug application (ANDA) filer on Tofacitinib extended-release tablets 22 mg and thus holds 180-day exclusivity on this strength, the company said in a statement. https://ift.tt/eA8V8J
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment